1. Home
  2. KPRX vs FBRX Comparison

KPRX vs FBRX Comparison

Compare KPRX & FBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KPRX
  • FBRX
  • Stock Information
  • Founded
  • KPRX 1998
  • FBRX N/A
  • Country
  • KPRX United States
  • FBRX United States
  • Employees
  • KPRX N/A
  • FBRX N/A
  • Industry
  • KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • FBRX Biotechnology: Pharmaceutical Preparations
  • Sector
  • KPRX Health Care
  • FBRX Health Care
  • Exchange
  • KPRX Nasdaq
  • FBRX Nasdaq
  • Market Cap
  • KPRX 9.8M
  • FBRX 59.5M
  • IPO Year
  • KPRX N/A
  • FBRX N/A
  • Fundamental
  • Price
  • KPRX $3.19
  • FBRX $5.91
  • Analyst Decision
  • KPRX Strong Buy
  • FBRX Strong Buy
  • Analyst Count
  • KPRX 1
  • FBRX 4
  • Target Price
  • KPRX $10.00
  • FBRX $77.58
  • AVG Volume (30 Days)
  • KPRX 41.2K
  • FBRX 21.6K
  • Earning Date
  • KPRX 03-24-2025
  • FBRX 03-17-2025
  • Dividend Yield
  • KPRX N/A
  • FBRX N/A
  • EPS Growth
  • KPRX N/A
  • FBRX N/A
  • EPS
  • KPRX 1.69
  • FBRX N/A
  • Revenue
  • KPRX $16,020,000.00
  • FBRX N/A
  • Revenue This Year
  • KPRX N/A
  • FBRX N/A
  • Revenue Next Year
  • KPRX N/A
  • FBRX N/A
  • P/E Ratio
  • KPRX $1.89
  • FBRX N/A
  • Revenue Growth
  • KPRX N/A
  • FBRX N/A
  • 52 Week Low
  • KPRX $2.91
  • FBRX $4.11
  • 52 Week High
  • KPRX $6.48
  • FBRX $28.68
  • Technical
  • Relative Strength Index (RSI)
  • KPRX 42.17
  • FBRX 21.73
  • Support Level
  • KPRX $2.91
  • FBRX $6.51
  • Resistance Level
  • KPRX $3.53
  • FBRX $9.90
  • Average True Range (ATR)
  • KPRX 0.18
  • FBRX 1.09
  • MACD
  • KPRX -0.01
  • FBRX -0.16
  • Stochastic Oscillator
  • KPRX 33.41
  • FBRX 0.00

About KPRX Kiora Pharmaceuticals Inc.

Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.

About FBRX Forte Biosciences Inc.

Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, and alopecia areata (AA).

Share on Social Networks: